

	Intolerant/ Toxicity	IM failure/no response	Planned HCT	p-value (IM failure/no response vs. planned HCT)
N (%)	17	66	97	
Age at HCT, n (%)				0.01
<=30	4 (23)	15 (23)	42 (43)	
31-40	3 (18)	14 (21)	24 (25)	
41-50	3 (18)	26 (39)	20 (21)	
>50	7 (41)	11 (17)	11 (11)	
Male, n (%)	9 (53)	32 (48)	58 (60)	0.15
White race, n (%)	11 (65)	53 (80)	83 (86)	0.37
Karnofsky at HCT, n (%)				0.50
<=80%	0	6 ( 9)	6 ( 6)	
>80%	16 (94)	52 (79)	78 (81)	
Missing	1 ( 6)	8 (12)	13 (13)	
Donor, n (%)				0.13
HLA sibling	6 (35)	23 (35)	20 (21)	
Other relative	0	1 ( 2)	2 ( 2)	
Unrelated	11 (65)	42 (64)	75 (77)	
Conditioning regimen, n (%)				0.02
Myeloablative	12 (71)	46 (70)	82 (85)	
Reduced intensity	5 (29)	20 (30)	15 (15)	
Graft type, n (%)				0.01
Bone marrow	9 (53)	28 (42)	60 (62)	
Peripheral blood	8 (47)	38 (58)	37 (38)	
Year of transplantation, n (%)				0.09
1999-2000	0	0	1 ( 1)	
2001-2002	6 (35)	12 (18)	31 (32)	
2003-2004	11 (65)	54 (82)	65 (67)	
Median follow-up of survivors, mos, median (range)	30 (22-56)	33 (8-60)	31 (12-65)	
Interval from diagnosis to HCT, mos, median (range)	15 (5-40)	15 (4-57)	11 (2-106)	<0.001
Duration of IM treatment, mos, median (range)	7 (1-36)	14 (0.6-47)	8 (0.16-55)	<0.001

Best IM response, n (%)				<0.001
None	3 (18)	8 (12)	7 ( 7)	
Molecular	1 ( 6)	2 ( 3)	13 (13)	
Cytogenetic <35%	2 (12)	8 (12)	26 (27)	
Cytogenetic >35%	4 (23)	27 (41)	14 (15)	
Hematological	5 (29)	19 (29)	36 (37)	
Missing	2 (12)	2 ( 3)	1 ( 1)	
Other drugs used to treat CML, n (%)				0.39
None	0	0	3 ( 3)	
Busulfan	0	1 ( 2)	0	
Hydroxyurea	14 (82)	47 (71)	69 (71)	
Interferon alpha	0	1 ( 2)	2 ( 2)	
Interferon gamma	0	0	1 ( 1)	
Anagrelide	0	3 ( 5)	1 ( 1)	
Others	3 (18)	13 (20)	20 (21)	
Hemoglobin: g/dL	13 (9-15)	12 (9-17)	12 (8-15)	0.005
Platelets: 10 <sup>9</sup> /L	232 (60-544)	222 (52-1568)	208 (88-593)	0.68
White blood count: 10 <sup>9</sup> /L	6 (2-57)	5 (1-141)	6 (3-72)	0.95
Blasts: %	0 (0-8)	0 (0-4)	0 (0-3)	0.19
EBMT score				0.01
0-1	1 ( 6)	4 ( 6)	12 (12)	
2	6 (35)	14 (21)	34 (35)	
3	3 (18)	25 (38)	36 (38)	
4	6 (35)	22 (33)	12 (12)	
5+	1 ( 6)	1 ( 2)	3 ( 3)	
<b>Outcomes</b>				
TRM at 1 yr	12 (1-31)	17 (9-27)	21 (13-30)	0.50
TRM at 3 yr	12 (1-31)	23 (14-34)	26 (18-36)	0.63
Relapse at 1 yr	18 (4-39)	27 (17-39)	8 (4-15)	0.002
Relapse at 3 yr	24 (7-46)	32 (21-45)	11 (5-18)	0.002
LFS at 1 yr	71 (47-89)	56 (44-67)	71 (61-79)	0.05
LFS at 3 yr	65 (41-85)	45 (0-100)	63 (52-72)	0.78
OS at 1 yr	82 (61-96)	79 (68-88)	79 (71-87)	0.90
OS at 3 yr	82 (61-96)	69 (57-79)	73 (63-81)	0.58

**Abbreviations:** IM = imatinib mesylate; HCT = hematopoietic cell transplantation; HLA = human leukocyte antigen;

CML = chronic myeloid leukemia; EBMT = European Blood and Marrow Transplantation; TRM = treatment-related mortality; LFS = leukemia-free survival; OS = overall survival.